Covid-19 vaccine
In the fight against Covid-19, India has accelerated its vaccination drive by making everyone above the age of 18 eligible to get the vaccine under Phase 3. In the next phase, Centre will allocate vaccines to the states and UTs based on the “criteria of the extent of infection and performance, i.e number of active Covid cases and speed of administration. The Centre has also mentioned that the wastage of vaccine will also be considered as criteria and will affect the criteria negatively.
Centre has also stated that the vaccination will continue as it is in vaccination centers and will be provided free of cost to the eligible population as defined earlier. These priority groups include Healthcare workers, front link workers and all above the age of 45 years.
Help us delete comments that do not follow these guidelines
by marking them offensive. Let s work together to keep the conversation civil.
Be the first one to review.
We have sent you a verification email. To verify, just follow the link in the message
Now Reading:
Highlights
Covaxin is developed by Bharat Biotech.
Serum Intitute and Bharat Biotech vaccines have to be administered in two doses.
In a significant development, Drugs Controller General of India (DCGI) on Sunday (January 3) formally approved Serum Institute s Covishield and Bharat Biotech s Covaxin for restricted use in India. Serum Intitute and Bharat Biotech vaccines have to be administered in two doses. All the three vaccines have to be stored at 2-8° C. After adequate examination, CDSCO has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situation and permission is being granted to M/s Cadila Healthcare for conduct of the Phase III clinical trial, DCGI said in a press statement.
Highlights
It is expected that the vaccination drive would now soon begin in the country.
The dry run of vaccines was conducted in all states and union territories on January 2.
In a significant development, the Drug Controller General of India (DCGI) on Sunday (January 2) formally approved Serum Institute and Bharat Biotech vaccines for restricted emergency use against COVID-19 in India. It is expected that the vaccination drive would now soon begin in the country. The dry run of vaccines was conducted in all states and union territories on January 2.
Here is all you need to know about Serum Institute s Covishield and Bharat Biotech s Covaxin:
Highlights
Covaxin is developed by Bharat Biotech.
Serum Intitute and Bharat Biotech vaccines have to be administered in two doses.
NEW DELHI: Prime Minister Narendra Modi on Sunday (January 3) hailed the Drugs Controller General of India (DCGI) s nod for Serum Institute s Covishield and Bharat Biotech s Covaxin for restricted use in India. The Prime Minister termed the move as a decisive turning point in the country’s fight against the virus and expressed his gratitude for all frontline workers in adverse circumstances .
In a series of tweets, Prime Minister Modi congratulated Serum Institute and Bharat Biotech on getting the DCGI’s approval. A decisive turning point to strengthen a spirited fight! DCGI granting approval to vaccines of @SerumInstIndia and @BharatBiotech accelerates the road to a healthier and COVID-free nation. Congratulations India. Congratulations to our hardworking scientists and innovators. DCGI approves restricted emergency use of Serum Institute,